Mobile

A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer

Update Il y a 4 ans
Reference: EUCTR2006-002321-23

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To estimate the time-to-progressive disease for patients who have received LY573636 after two prior treatment regimens of systemic therapy for unresectable, metastatic non-small cell lung cancer (NSCLC).

Inclusion criteria

  • Unresectable, metastatic non-small cell lung cancer (NSCLC)

Links